Liveyon Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Liveyon's estimated annual revenue is currently $4.5M per year.(i)
  • Liveyon's estimated revenue per employee is $155,000

Employee Data

  • Liveyon has 29 Employees.(i)
  • Liveyon grew their employee count by -36% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Liveyon LLC is the exclusive worldwide distributor of a regenerative medicine product that is derived from umbilical cord. This product contains cells, stem cells and growth factors which may serve as a therapy for various degenerative diseases/disorders. Stem cells and cell based therapies have shown tremendous promise; yet controlled studies are still needed in order to confirm its efficacy. Professional judgment and expertise is needed in using these therapies for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies or any regenerative medicine product to consult the national health data bases to evaluate current information from clinical trials. The FDA websites on human tissue should also be consulted to get its current evaluation of any regenerative therapy. Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based or regenerative medicine products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.

keywords:N/A

N/A

Total Funding

29

Number of Employees

$4.5M

Revenue (est)

-36%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Liveyon News

2019-09-07 - Google will stop selling ads for untested stem cell therapies

The suit alleges she was harmed by umbilical cord products tainted with E. coli, sold by Liveyon, a Nevada-based stem cell distributor. Several ...

2019-08-24 - KC woman got E. coli infection from stem cell treatment at JoCo clinic, lawsuit says

The suit alleges she was harmed by tainted umbilical cord products sold by Liveyon, a Nevada-based stem cell distributor. Liveyon's ReGen ...

2019-08-17 - Peddling unproven treatments, stem cell industry ‘fleeces,’ sometimes harms patients

Lunceford's was one of 12 hospitalizations that the Centers for Disease Control linked to products sold by Liveyon, a California-based ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.5M2921%N/A
#2
$2.4M2912%N/A
#3
$3.6M297%$20M
#4
$4.6M2945%N/A
#5
$2.9M29N/AN/A